Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Schroeder

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Nursing Care Quality|April 12, 2003
We've made progress, but there's a long way to goPatricia Schroeder
Journal of Nursing Care Quality|April 4, 2002
How can the public identify an excellent healthcare organization?Patricia Schroeder
Nursing Management|August 29, 2019
Healthcare quality improvement: Then and nowPatricia Schroeder, Lenard L Parisi, Rhonda Foster
Plos One|October 22, 2014
Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeuticsGary Mo, Frank Gibbons, Patricia Schroeder, et al.
BMC Gastroenterology|April 1, 2014
Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriatenessEmanuel Burri, Michael Manz, Patricia Schroeder, et al.
Journal of Toxicologic Pathology|May 3, 2014
Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B InhibitorJane C F Chang, Paul Ciaccio, Patricia Schroeder, et al.
American Journal of Cancer Research|May 18, 2016
M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrierAndreas Machl, Erik W Wilker, Hui Tian, et al.
Brain, Behavior, and Immunity|October 1, 2020
Abnormal brain structure and behavior in MyD88-deficient micePatricia Schroeder, Marion Rivalan, Sami Zaqout, et al.
Neuropharmacology|June 18, 2017
Broad analgesic activity of a novel, selective M1 agonistMichael W Wood, Giovanni Martino, Martin Coupal, et al.
Clinical Pharmacology in Drug Development|January 12, 2022
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 TrialSanjeev Forsyth, Patricia Schroeder, James Geib, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Nursing Care Quality|April 12, 2003
We've made progress, but there's a long way to goPatricia Schroeder
Journal of Nursing Care Quality|April 4, 2002
How can the public identify an excellent healthcare organization?Patricia Schroeder
Nursing Management|August 29, 2019
Healthcare quality improvement: Then and nowPatricia Schroeder, Lenard L Parisi, Rhonda Foster
Plos One|October 22, 2014
Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeuticsGary Mo, Frank Gibbons, Patricia Schroeder, et al.
BMC Gastroenterology|April 1, 2014
Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriatenessEmanuel Burri, Michael Manz, Patricia Schroeder, et al.
Journal of Toxicologic Pathology|May 3, 2014
Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B InhibitorJane C F Chang, Paul Ciaccio, Patricia Schroeder, et al.
American Journal of Cancer Research|May 18, 2016
M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrierAndreas Machl, Erik W Wilker, Hui Tian, et al.
Brain, Behavior, and Immunity|October 1, 2020
Abnormal brain structure and behavior in MyD88-deficient micePatricia Schroeder, Marion Rivalan, Sami Zaqout, et al.
Neuropharmacology|June 18, 2017
Broad analgesic activity of a novel, selective M1 agonistMichael W Wood, Giovanni Martino, Martin Coupal, et al.
Clinical Pharmacology in Drug Development|January 12, 2022
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 TrialSanjeev Forsyth, Patricia Schroeder, James Geib, et al.
Pageof 3